The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.
 
Sumanta Kumar Pal
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
Melissa Andrea Reimers
Honoraria - Society of Urologic Nurses and Associates (SUNA)
Consulting or Advisory Role - Loxo; Pathos AI, Inc
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS GmbH & Co. KG (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Genentech (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); ProfoundBio (Inst)
 
Benjamin Garmezy
Research Funding - Abbvie (Inst); Abbvie (Inst); Accutar Biotech (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); crispr therapeutics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Genentech (Inst); Harbour BioMed (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Xencor (Inst); Zenshine (Inst); Zenshine (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AVEO (Inst); Bayer (Inst); Eisai (Inst); Exelixis (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Wenxin Xu
Consulting or Advisory Role - Aveo; Exelixis; Jazz Pharmaceuticals; Merck; Xencor
Research Funding - Oncohost (Inst)
 
Christopher J. Hoimes
Honoraria - Seagen
Consulting or Advisory Role - 2bPrecise; Amgen (Inst); Bristol-Myers Squibb; crispr therapeutics (Inst); Eisai; Genentech/Roche; Merck Sharp & Dohme; NeoImmuneTech (Inst); Prometheus; Seagen
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Seagen
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); Bristol Myers Squibb Foundation (Inst); crispr therapeutics (Inst); Dynavax Technologies (Inst); Janssen Oncology (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); NanoCarrier (Inst); Nektar (Inst); NeoImmuneTech (Inst); Novartis (Inst); seagen (Inst)
(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst)
 
Michael Weinstein
Employment - Crispr Therapeutics
Stock and Other Ownership Interests - Crispr Therapeutics
 
Erika L Cullingford
Employment - Crispr Therapeutics
Stock and Other Ownership Interests - Crispr Therapeutics
 
Anna Ma
Employment - Crispr Therapeutics
Stock and Other Ownership Interests - Crispr Therapeutics
 
Leah M Williams
Employment - Crispr Therapeutics
Stock and Other Ownership Interests - Crispr Therapeutics
 
Henia Dar
Employment - Crispr Therapeutics
Stock and Other Ownership Interests - Crispr Therapeutics
 
Alissa Keegan
Employment - Crispr Therapeutics
Stock and Other Ownership Interests - Crispr Therapeutics
 
Samer Ali Srour
Consulting or Advisory Role - Hansa Biopharma; Novartis